The Brucella species type IV secretion system, encoded by the virB1-12 locus, is required for intracellular replication and persistent infection in vivo. The requirement of VirB proteins for infection suggests that they are expressed in vivo and may therefore represent serological markers of infection. To test this idea, we purified recombinant VirB1, VirB5, VirB11, and VirB12 and tested for their recognition by antibodies in sera from experimentally infected mice and goats by using an indirect enzyme-linked immunosorbent assay. Antibody responses to VirB12 but not to VirB1, VirB5, or VirB11 were detected in 20/20 mice experimentally inoculated with Brucella abortus and 12/12 goats experimentally infected with Brucella melitensis. The potential use of VirB12 as a serological tool for the diagnosis of brucellosis was evaluated in the natural bovine host. Serum samples from 145 cattle of known serology (29% negative and 71% positive) were analyzed for the production of antibody responses to VirB12. One hundred two cattle samples (70.3%) were positive for antibodies to VirB12, while 43 samples were negative (29.7%). A positive serological response to VirB12 correlated with positive serology to whole B. abortus antigen in 99% of samples tested. These results show that VirB12 is expressed during infection of both experimental and natural hosts of Brucella species, and they suggest that VirB12 may be a useful serodiagnostic marker for brucellosis.
Brucella strains are the causative agents of brucellosis, which can affect both animals and humans. The disease is characterized by bacterial persistence in the reticuloendothelial system, including the liver, spleen, and lymph nodes, and infection may result in abortion in infected ruminants (34) . Zoonotic transmission of the bacteria to humans is caused by accidental contamination from unpasteurized animal products or infected animals.
The type IV secretion system (T4SS) is encoded by the virB locus, located on chromosome II, and includes virB1 to virB12 (2, 3) . The T4SS of Brucella spp. has been shown to be an essential virulence factor, and T4SS mutants are highly attenuated in tissue culture models of intracellular survival, in the mouse model of persistent infection (3, 5-8, 10, 14, 23, 30, 32) , and in the goat, a natural host for Brucella melitensis (12) . A functional T4SS is not required for initial colonization in mice but is required for evasion of immune responses activated during the first week of infection (25, 27) .
Several diagnostic tools are used for the detection of brucellosis. While bacteriological isolation is the most specific diagnostic test, the frequency of isolation is usually low, and results are not available immediately. For this reason, serological tests are widely used for diagnosis of human and animal brucellosis (1) . Classical serological techniques rely on the detection of smooth lipopolysaccharide (LPS), but false-positive reactions may occur due to cross-reactivity with LPS from other bacteria (21, 22, 33) . The shortcomings of the classical serological tests have sparked increasing interest in finding alternative antigens to detect brucellosis.
Secreted or cell envelope-associated bacterial proteins are often antigenic in the context of infection. Proteins associated with the cell envelope of Brucella species have previously been shown to elicit antibody responses in both experimentally and naturally infected animals (4, 17-19, 24, 26) . Further, VirB proteins from other bacteria, including Ehrlichia canis and Anaplasma marginale, have been shown to be immunogenic (9, 20) . Since the Brucella abortus T4SS has been shown to be expressed during infection and encodes an apparatus that assembles at the surface of the cell, we tested whether the components of the T4SS apparatus are immunogenic and whether responses to these proteins can be used as serological indicators of infection with Brucella species. We have previously shown that mice infected with B. abortus 2308 produced an antibody response to the protein encoded by the virB12 gene (31) . In this study, we used purified recombinant VirB1, VirB5, VirB11, and VirB12 to assess the antibody responses to these proteins in sera from mice experimentally infected with B. abortus, from goats experimentally infected with B. melitensis, and from cattle of known serological status for Brucella.
MATERIALS AND METHODS
Bacterial strains, media, and culture conditions. Escherichia coli cultures were grown on Luria-Bertani (Difco, Becton Dickinson, Sparks, MD) plates or in Luria-Bertani broth at 37°C with or without antibiotics. Brucella abortus 2308, Brucella melitensis 16M, and isogenic mutant strains were cultured on tryptic soy agar (Difco, Becton Dickinson, Sparks, MD) or in tryptic soy broth at 37°C on a rotary shaker. Their characteristics are listed in Table 1 . Bacterial inocula for infection of mice were cultured on tryptic soy agar plus 5% blood. All work with live Brucella species was performed at biosafety level 3.
Infection of mice. Female C57BL/6J and BALB/c ByJ mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and used at the ages of 8 to 10 weeks. Mice were held in microisolator cages with sterile bedding and water and irradiated feed in a biosafety level 3 facility. For infection experiments, groups of 10 to 20 mice were inoculated intraperitoneally with 0.1 ml of phosphate-buffered saline (PBS) containing 5 ϫ 10 5 CFU of B. abortus 2308 or an isogenic ⌬virB1-12 mutant (complete deletion of the virB locus). Ten age-matched mice were injected with PBS. For assaying specific antibody responses, blood samples were collected from the saphenous vein before infection (infected mice) and once a week for 10 weeks after infection for both infected and PBS-treated mice. All animal experiments were approved by the Texas A&M University Laboratory Animal Care and Use Committee and were conducted in accordance with institutional guidelines.
Goat serum samples. Twelve serum samples from experimentally infected goats were used in this study. Animals were infected, and sera were collected, as described previously by us (12) . Briefly, female Angora goats averaging 110 days of gestation were infected at 1 ϫ 10 7 CFU via bilateral conjunctival inoculation, and sera were collected 8 weeks after infection. Goats (three per group) were infected with B. melitensis 16M or the BM⌬asp24, BM⌬virB2 (nonpolar), or BM⌬cydBA isogenic mutant. Serum samples from 12 naïve goats were also used.
Bovine serum samples. One hundred forty-five serum samples of known serology (as determined by the brucellosis card test and an enzyme-linked immunosorbent assay [ELISA] with whole Brucella antigen) were used in this study. One hundred three seropositive samples were from the investigators' specimen collection. The 42 known negative samples were obtained from male calves housed at a dairy calf-rearing operation in Texas, since male dairy calves are not vaccinated against brucellosis.
Purification of GST-VirB1 and GST-VirB5. E. coli BL21 carrying pMO4 (glutathione S-transferase [GST]-VirB1) or E. coli BL21 carrying pAV5.1 (GSTVirB5) was grown in 20 ml of LB containing 100 g/liter of carbenicillin (LB plus Carb) at 37°C. Expression of GST-VirB1 or GST-VirB5 was induced with 1 mM isopropyl-␤-D-thiogalactopyranoside (IPTG) at 37°C. Bacteria were resuspended in 1 ml of PBS buffer containing 2% Tween 20 and protease inhibitor cocktail (Sigma). Cells were lysed by sonication and centrifuged, and the supernatant was mixed with 2 ml of glutathione Sepharose 4B (Amersham Bioscience, Piscataway, NJ) beads and incubated for 1 h at 4°C. The slurry was transferred to a column and washed three times with cold PBS. The protein was eluted by adding 1 ml of elution buffer (0.031 g reduced glutathione in 10 ml of 10 mM Tris-HCl [pH 8.0]). GST-VirB1 and GST-VirB5 were concentrated using Amicon Ultra-15 (Millipore) concentration tubes.
Removal of the GST tag from VirB1 and VirB5. To avoid measuring serological responses to the GST moiety of GST fusion proteins, the GST tag was removed from GST-VirB1 and GST-VirB5 by incubation with thrombin at room temperature for 2 h. The reaction mixture was mixed with 1 ml of glutathione Sepharose 4B (Amersham Bioscience, Piscataway, NJ) beads and incubated for 1 h at 4°C. The slurry was transferred to a column and washed once with cold PBS (the wash contained the protein of interest). VirB1 and VirB5 were concentrated using Amicon Ultra-15 (Millipore) concentration tubes and were dialyzed twice against PBS (pH 7.4).
Purification of recombinant VirB11. Strep-VirB11 was purified according to the manufacturer's (IBA, Germany) protocol. Briefly, E. coli BL21 carrying pT7-7Strep::virB11 was grown for 16 h in 2 liters of LB plus Carb at 37°C. On the following day, expression of Strep-VirB11 was induced with 1 mM IPTG for 16 h at room temperature. Bacteria were resuspended in 40 ml of washing buffer with 0.5 mM phenylmethylsulfonyl fluoride. Bacteria were lysed with a French press and pelleted twice at 11,000 rpm, and the supernatant was transferred to a 5-ml column of streptactin beads (IBA) that was equilibrated with 2 column volumes (CV) of buffer W (100 mM Tris-HCl [pH 8], 150 mM NaCl, 1 mM EDTA). The beads were washed twice with 5 CV of buffer W, and the protein was eluted with 6ϫ 0.5 CV buffer E (buffer W plus 2.5 mM desthiobiotin). Strep-VirB11 was concentrated using Amicon Ultra-15 (Millipore) concentration tubes and was dialyzed twice against PBS (pH 7.4).
Purification of recombinant VirB12. E. coli BL21 carrying pDS1 (His 6 -VirB12) was grown in 20 ml of LB plus Carb at 37°C. Expression of His 6 -VirB12 was induced with 1 mM IPTG at 37°C. VirB12 was purified under denaturing conditions using reagents from Qiagen (Valencia, CA). Briefly, after induction, cells were lysed with lysis buffer (100 mM NaH 2 Detection of VirB12-specific IgG in serum samples. The presence of antibody specific for the recombinant B. abortus VirB12 protein in the sera of mice, goats, and cattle was determined by an indirect ELISA. Nickel-nitrilotriacetic acid HisSorb plates from Qiagen (Valencia, CA) were coated with 100 ng of HisVirB12 per well in carbonate buffer (pH 9.6), and plates were incubated at 4°C overnight. After a wash with PBS and 0.05% Tween 20 (PBS-T), mouse serum samples (1:100), goat serum samples (1:16,000), or bovine serum samples (1: 16,000) were diluted in PBS-B for mouse samples (PBS, 0.05% Tween 20, and 2% bovine serum albumin) or PBS-G for goat and bovine samples (PBS, 0.05% Tween 20, and 2% gelatin) and were incubated at 37°C for 1 h. After a wash with PBS-T, the reactivity was measured using horseradish peroxidase-conjugated anti-mouse (1:1,000; BD Pharmingen), anti-goat (1:5,000; Jackson ImmunoResearch), or anti-bovine (1:5,000; Jackson ImmunoResearch) immunoglobulin G (IgG) by incubating the plates at 37°C for 1 h. The reaction was developed with Sigma Fast o-phenylenediamine dihydrochloride tablet sets. The resulting color was read at 450 nm with an ELISA microplate reader (Bio-Rad model 680). Data points are the averages of duplicate dilutions, and each measurement was performed twice.
Detection of VirB1-specific, VirB5-specific, and VirB11-specific IgG. The presence of antibody specific for the recombinant proteins VirB1, VirB5, and VirB11 of Brucella abortus in the sera of mice, goats, and cattle was determined by ELISA. MaxiSorp plates from Qiagen (Valencia, CA) were coated with 100 ng of VirB1, VirB5, or VirB11 per well in carbonate buffer (pH 9.6), and plates were incubated at 4°C overnight. ELISA was performed as described above. Data points are the averages of duplicate dilutions, and each measurement was performed twice.
Detection of Brucella-specific IgG. The presence of antibody specific for wholecell antigen of B. abortus in the sera of mice, goats, and cattle was determined by ELISA. MaxiSorp plates from Qiagen (Valencia, CA) were coated with 100 l formalin-killed whole B. abortus (1 g/ml) in carbonate buffer (pH 9.6), and plates were incubated at 4°C overnight. Mouse serum samples were diluted 1:100, while goat and cattle samples were measured at a dilution of 1:16,000. ELISAs were performed as described above. Data points are the averages of duplicate dilutions, and each measurement was performed twice. Statistical analysis. For determination of statistical significance between experimental groups and naïve groups, Student's t test was performed on the data. A P value of Ͻ0.05 was considered significant.
RESULTS

B. abortus-infected mice develop antibody responses specific
for VirB12 but not for VirB1, VirB5, or VirB11. To determine whether VirB1, VirB5, VirB11, and VirB12 can serve as serological markers of infection with Brucella spp., we assayed the antibody responses of infected mice for IgG specific for VirB1, VirB5, VirB11, and VirB12. Serum samples were obtained from mice infected with either B. abortus 2308 or the ⌬virB1-12 mutant (a mutant strain carrying a complete deletion of the virB locus) or from age-matched uninfected controls. We have previously shown that for B. abortus-infected mice, the level of IgG specific for VirB12 increased over that for naïve mice starting at 3 weeks after infection (with the highest response at weeks 8 to 10), while that for mice infected with a ⌬virB12 mutant (in which only virB12 was deleted) did not differ from the preinoculation level (31) . The results in Fig. 1 show that at week 9 after infection, levels of IgG-specific for VirB1, VirB5, and VirB11 in preinfection samples or samples from naïve age-matched mice did not differ from those for mice infected with either 2308 or the ⌬virB1-12 mutant. When mice were infected with the ⌬virB1-12 mutant, levels of VirB12-specific IgG did not differ from those in preinfection samples or agematched naïve mice. VirB12-specific IgG levels did, however, increase in mice infected with B. abortus 2308 (wild type) over those in naïve mice, as previously described (31) . These results indicate that VirB12 elicits an antibody response during infection of mice, while VirB1, VirB5, and VirB11 do not.
VirB12, but not VirB1, VirB5, or VirB11, is immunogenic in goats. To determine whether VirB1, VirB5, VirB11, and VirB12 elicited antibody responses in a natural host for Brucella, we obtained sera from 12 goats experimentally infected with B. melitensis 16M or its isogenic mutant BM⌬asp24, BM⌬virB2 (nonpolar), or BM⌬cydBA (12) and sera from 12 naïve goats. The levels of IgG specific for VirB1 ( Fig. 2A) , VirB11 (Fig. 2B ), or VirB5 (Fig. 2C ) determined by ELISA did not differ between naïve goats and goats infected with either wild-type B. melitensis 16M or any of the mutant strains. In contrast, for all four groups of animals infected with B. melitensis strains, the levels of IgG-specific for VirB12 (Fig. 2D ) increased significantly above those measured for naïve goats. These results indicate that VirB12 is expressed in vivo and generates a host response during infection of goats, while VirB1, VirB5, and VirB11 do not appear to elicit antibody responses.
To correlate serological responses to VirB12 with responses to whole-cell antigen, we performed ELISA on the goat serum samples using whole-cell Brucella antigen (Fig. 3A) . The serology response to Brucella IgG was confirmed with the brucellosis card test. Goats infected with B. melitensis ⌬virB2 (nonpolar) did not exhibit IgG responses to whole-cell Brucella antigen, while for goats infected with 16M or the ⌬asp24 mutant and for two of the goats infected with the ⌬cydBA mutant, anti-Brucella IgG levels increased over those for naïve controls, in agreement with previous results reported by Kahl-McDonagh et al. (12) .
The correlation between levels of IgG specific for whole-cell Brucella antigen and VirB12-specific IgG is shown in Fig. 3B . Three goats infected with B. melitensis ⌬virB2 and one goat infected with B. melitensis ⌬cydBA did not develop high levels of Brucella-specific IgG antibody but produced high levels of anti-VirB12 antibody. The remaining infected goats generated both a high Brucella-specific IgG response and a high VirB12-specific response. For all 12 infected goats, positive antibody responses to VirB12 were observed.
Cattle seropositive for Brucella also develop an immune response to VirB12. To explore the potential of VirB12 as a serological marker of infection in cattle, we measured VirB12-specific IgG by ELISA in 145 cattle samples of known B. abortus serology (Fig. 4) . We obtained 42 seronegative and 103 seropositive samples. In serum samples from 102 cattle, IgG specific for VirB12 was detected, with a mean A 450 of 0.792 Ϯ FIG. 1 . Detection of anti-VirB antibodies in sera from mice experimentally infected with wild-type Brucella abortus 2308 or its ⌬virB1-12 isogenic mutant. Ten to 20 mice were infected intraperitoneally with 2308 or a ⌬virB1-12 mutant. Blood was collected before infection and 9 weeks after infection. Ten age-matched mice were treated with PBS, and blood was collected 9 weeks later. Antibodies specific for VirB1, VirB5, VirB11, and VirB12 (␣-VirB1, ␣-VirB5, ␣-VirB11, and ␣-VirB12) were detected by ELISA. Data are presented as the A 450 of a 1:100 dilution of serum. Each bar indicates the average Ϯ standard deviation of triplicate samples. ND, not determined. Asterisk indicates statistical significance, determined by Student's t test. A P value of Ͻ0.05 was considered significant.
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on September 6, 2017 by guest http://cvi.asm.org/ 0.221. For the 43 cattle samples showing no response to VirB12, the mean A 450 was 0.061 Ϯ 0.046. The correlation between IgG responses specific for Brucella whole-cell antigen and for VirB12 is shown in Fig. 4 . One hundred two samples (70.3%) were serologically positive for both Brucella and VirB12. Forty-two samples (29%) were serologically negative for both whole-cell antigen and VirB12. One animal (0.7%) showed a seropositive result for whole Brucella antigen, but no VirB12-specific IgG was detected. Overall, serological results for whole-cell antigen and VirB12 were concordant for 99% of samples.
DISCUSSION
This study was undertaken to determine whether individual proteins encoded by the virB locus, which assemble to form a secretion apparatus at the surface of the bacterium, are immunogenic and whether serological responses to these proteins can be used for detection of brucellosis.
We purified recombinant VirB1, VirB5, VirB11, and VirB12 antigens and evaluated their potential use for the serological diagnosis of brucellosis by ELISA. Evidence of VirB12 expression ( Fig. 1) was detected in mice infected with B. abortus: an IgG response specific for VirB12 was elicited after infection with B. abortus 2308 but not after infection with a mutant lacking the entire virB locus. The cell surface localization of VirB12 may contribute to its immunogenicity, as well as the fact that it is a predicted lipoprotein. VirB1, VirB5, and VirB11 also assemble in the membrane of the bacterium (16, 28) , but we could not find evidence of specific antibody response against these proteins in the mouse or the goat model. One possible explanation for this result that we cannot exclude is that the recombinant VirB1, VirB5, and VirB11 antigens used for indirect ELISA were not in their native conformations, which would negatively impact the performance of our detection assay. However, a lack of immunogenicity of VirB1 and VirB5 could benefit Brucella during infection, since in the closely related bacterium Agrobacterium tumefaciens, these two proteins have been shown to be part of a pilus structure that protrudes from the bacterial surface and is therefore exposed to the immune system (15) .
The BM⌬asp24, BM⌬virB2, and BM⌬cydBA mutants used in our study have been assessed as vaccine candidates in the goat and mouse models of infection (12, 13) . Both the BM⌬asp24 and BM⌬virB2 mutants have shown promise as safe vaccine candidates in mouse and goat models. BM⌬asp24 was able to colonize the maternal tissues but not the fetal tissues and cause seroconversion in goats, while BM⌬virB2 was not capable of colonizing maternal or fetal tissues and did not cause seroconversion. The BM⌬cydBA mutant was as virulent in the pregnant goat model as 16M (12) .
Goats infected with B. melitensis 16M or the BM⌬asp24, BM⌬virB2, or BM⌬cydBA mutant elicited a response specific for VirB12, but not for VirB1, VirB5, or VirB11. BM⌬virB2 is a nonpolar mutation of VirB2; thus, VirB3 to VirB12 are expected to be expressed during infection (8) . Goats infected with BM⌬virB2 did not seroconvert to whole-cell Brucella antigen ( Fig. 3 ) (12) but exhibited a strong VirB12 response. One of the goals for the development of vaccines and diagnostic tools for brucellosis is a test that can distinguish between vaccinated and naturally infected animals. Our results show the potential of using VirB12 for such a goal, since BM⌬virB2 was found to be a safe vaccine with no seroconversion by using the brucellosis card test and whole-cell ELISA but elicited an As shown in Fig. 4 , antibodies to VirB12 were detected in 70.3% (102 of 145) of bovine serum samples tested, while 29.7% of the samples did not give a response to VirB12. One of the 145 cattle samples was serologically positive for Brucella but negative for antibodies specific to VirB12. Serological tests for brucellosis may yield false-positive results for cattle vaccinated with B. abortus S19 or exposed to gram-negative bacteria with LPS O-chains similar to those of Brucella, such as Yersinia enterocolitica O:9. The cross-reactivity between Y. enterocolitica O:9 and Brucella is due to a strong similarity of the LPS O-chains (21, 33) . We do not know if this animal showed serological reactivity to Brucella due to cross-reactivity with Y. enterocolitica O:9 or other bacteria, such as E. coli O157:H7, a frequent colonizer of cattle. Since we did not detect seroreactivity to VirB12, either this animal may have been infected and did not respond to VirB12 or it had a serological cross-reaction to whole cells elicited by bacteria other than Brucella. Based on the information at hand, we are unable to distinguish between these two possibilities.
In summary, this study shows that antibodies to B. abortus VirB12 can be identified in mice, goats, and cattle. One hundred percent of the experimentally infected mice and goats generated specific responses to VirB12, including those infected with mutants shown to be promising vaccine candidates (12, 13) . These results encourage further investigation with patient samples to determine whether detection of humoral responses to VirB12-specific immune responses can be used for the diagnosis of human brucellosis.
